 |
|
|
| |
Efimosfermin Alfa Once-Monthly Treatment Improves Collagen Biomarker Profiles and Rapidly Induces Histological Fibrosis Regression in Subjects with MASH Stage F2-F3 Fibrosis in a 24-week Phase 2 Trial
|
| |
| |
Rohit Loomba, MD, MHSc; Kris V. Kowdley, MD; Gerard Bain, PhD; Matthew D. Bryant, PharmD; Margaret James Koziel, MD; Mazen Noureddin, MD, MHSc
EASL 2025 May 7-10 Amsterdam
|
| |
|
|
|
|
|
